COO of SAB Biotherapeutics (SABS) receives 1.8M option grant

Rhea-AI Filing Summary

SAB Biotherapeutics reported that its Chief Operating Officer, Christoph Lawrence Bausch, received a grant of stock options. On 02/03/2026, he was awarded options to purchase 1,800,000 shares of common stock at an exercise price of $4.45 per share. These options were granted under the company’s 2021 Omnibus Equity Incentive Plan, as amended. The award vests over four years, with one-quarter vesting on the first anniversary of the grant date and the remaining three-quarters vesting in 36 equal monthly installments thereafter. Following this grant, Bausch holds 1,800,000 stock options directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bausch Christoph Lawrence

(Last) (First) (Middle)

777 W 41ST STREET, SUITE 401

(Street)

MIAMI BEACH FL 33140

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SAB Biotherapeutics, Inc. [ SABS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF OPERATING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$4.45	02/03/2026		A		1,800,000(1)		(2)	02/03/2036	Common Stock	1,800,000	$0	1,800,000	D

Explanation of Responses:

1. Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.

2. The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

	/s/ Christoph Bausch	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did SAB Biotherapeutics (SABS) disclose about its COO in this Form 4?

SAB Biotherapeutics disclosed that Chief Operating Officer Christoph Lawrence Bausch received a stock option grant. The award covers 1,800,000 options to buy common shares at $4.45 each, granted under the company’s 2021 Omnibus Equity Incentive Plan, as amended.

How many SAB Biotherapeutics (SABS) stock options were granted to the COO?

The COO, Christoph Lawrence Bausch, was granted 1,800,000 stock options. Each option allows the purchase of one share of SAB Biotherapeutics common stock, giving him the right to buy up to 1,800,000 shares if the options vest and are exercised.

What is the exercise price of the SAB Biotherapeutics (SABS) options granted to the COO?

The stock options granted to the COO have an exercise price of $4.45 per share. This means he can purchase SAB Biotherapeutics common stock at $4.45 for each option, subject to the vesting schedule and the option’s 02/03/2036 expiration date.

How do the SAB Biotherapeutics (SABS) COO stock options vest over time?

The COO’s options vest over four years. One-quarter of the 1,800,000 options vests on the one-year anniversary of the 02/03/2026 grant date, and the remaining three-quarters vest in 36 equal monthly installments after that anniversary.

Under which plan were the SAB Biotherapeutics (SABS) COO options granted?

The options were granted under SAB Biotherapeutics’ 2021 Omnibus Equity Incentive Plan, as amended. This plan governs equity awards like stock options and is used to grant incentives tied to the company’s common stock to eligible participants.

What is the expiration date of the SAB Biotherapeutics (SABS) COO stock options?

The stock options granted to the COO expire on 02/03/2036. He may exercise vested options any time before that expiration date, subject to the plan’s terms and the four-year vesting schedule described in the disclosure.